A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer (Q45072371)
Jump to navigation
Jump to search
scientific article published in October 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer |
scientific article published in October 2004 |
Statements
1 reference
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer (English)
1 reference
1 reference
A Clamp
1 reference
M Adams
1 reference
R Atkinson
1 reference
E Boven
1 reference
A H Calvert
1 reference
A Cervantes
1 reference
T Ganesan
1 reference
J Lotz
1 reference
P Vasey
1 reference
P Cheverton
1 reference
1 October 2004
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference